☰

David L. Bourdet, Ph.D. - Publications

Affiliations: 
2005 University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Pharmacy, Pharmaceutical Chemistry
Tree Info Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. Bmj Open Respiratory Research. 10. PMID 37460276 DOI: 10.1136/bmjresp-2023-001627  0.728
2021 Pfeifer ND, Lo A, Bourdet DL, Colley K, Singh D. Phase 1 study in healthy participants to evaluate safety, tolerability and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19. Clinical and Translational Science. PMID 34318597 DOI: 10.1111/cts.13123  0.687
2021 Singh D, Bogus M, Moskalenko V, Lord R, Moran EJ, Crater GD, Bourdet DL, Pfeifer ND, Woo J, Kaufman E, Lombardi DA, Weng EY, Nguyen T, Woodcock A, Haumann B, et al. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. The European Respiratory Journal. PMID 34210790 DOI: 10.1183/13993003.00673-2021  0.705
2021 Singh D, Bogus M, Moskalenko V, Lord R, Moran EJ, Crater GD, Bourdet DL, Pfeifer ND, Woo J, Kaufman E, Lombardi DA, Weng EY, Nguyen T, Woodcock A, Haumann B, et al. A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19. The European Respiratory Journal. PMID 34210790 DOI: 10.1183/13993003.00673-2021  0.705
2020 Kanodia J, Lo A, Baldwin RM, Graham RA, Bourdet DL. Pharmacokinetics of Ampreloxetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain. Clinical Pharmacokinetics. PMID 32856281 DOI: 10.1007/S40262-020-00918-7  0.406
2020 Kanodia J, Lo A, Baldwin RM, Colley K, Zhou K, Bourdet DL. Safety, Pharmacokinetics and Pharmacodynamics of TD-0714, a Novel Potent Neprilysin Inhibitor in Healthy Adult and Elderly Subjects. Clinical and Translational Science. PMID 32506827 DOI: 10.1111/Cts.12831  0.385
2019 Borin MT, Barnes CN, Darpo B, Pendyala S, Xue H, Bourdet DL. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study. Clinical Pharmacology in Drug Development. PMID 31468714 DOI: 10.1002/Cpdd.732  0.425
2019 Donohue JF, Feldman G, Sethi S, Barnes CN, Pendyala S, Bourdet D, Crater G. Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials. Pulmonary Pharmacology & Therapeutics. 101808. PMID 31152911 DOI: 10.1016/J.Pupt.2019.101808  0.343
2019 Czerniak R, Chen Y, Aldairy W, Barnes C, Bourdet D, Almansa C, Chen C. Mo1581 – Evaluation of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of Tak–954 in a Randomized, Placebo-Controlled Phase 1 Study Gastroenterology. 156: S-789. DOI: 10.1016/S0016-5085(19)38925-5  0.438
2018 Kenna JG, Taskar KS, Battista C, Bourdet DL, Brouwer KLR, Brouwer KR, Dai D, Funk C, Hafey MJ, Lai Y, Maher J, Anne Pak Y, Pedersen JM, Polli JW, David Rodrigues A, et al. Can BSEP Inhibition Testing In Drug Discovery And Development Reduce Liver Injury Risk? - An International Transporter Consortium Perspective. Clinical Pharmacology and Therapeutics. PMID 30137645 DOI: 10.1002/Cpt.1222  0.306
2017 Quinn D, Barnes CN, Yates W, Bourdet DL, Moran EJ, Potgieter P, Nicholls A, Haumann B, Singh D. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies. Pulmonary Pharmacology & Therapeutics. PMID 28987804 DOI: 10.1016/j.pupt.2017.10.003  0.305
2017 Kanodia J, Baldwin M, Lo A, Wang D, Zhou K, Lee J, Colley K, Wang W, Bourdet D. Safety, Pharmacokinetics and Pharmacodynamics of TD-0714, a Novel Non-Renally Cleared Neprilysin Inhibitor, in Healthy Humanvolunteers: Potential for Once-Daily Dosing and Predictable Exposure in Patients Regardless of Baseline Renal Function Journal of Cardiac Failure. 23: S68. DOI: 10.1016/J.Cardfail.2017.07.192  0.364
2016 Proctor WR, Ming X, Bourdet D, Han TK, Everett RS, Thakker DR. Why Does the Intestine Lack Basolateral Efflux Transporters for Cationic Compounds? A Provocative Hypothesis. Journal of Pharmaceutical Sciences. 105: 484-96. PMID 26869413 DOI: 10.1016/J.Xphs.2015.11.040  0.67
2015 Smith JA, Bourdet DL, Patil DL, Daniels OT, Ding YS, Gallezot JD, Henry S, Kim KH, Kshirsagar S, Martin WJ, Obedencio GP, Stangeland E, Tsuruda PR, Williams W, Carson RE, et al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18. PMID 25522383 DOI: 10.1093/ijnp/pyu027  0.362
2012 Bourdet DL, Tsuruda PR, Obedencio GP, Smith JA. Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. The Journal of Pharmacology and Experimental Therapeutics. 341: 137-45. PMID 22235148 DOI: 10.1124/Jpet.111.188417  0.352
2008 Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1650-8. PMID 18458049 DOI: 10.1124/Dmd.107.020180  0.564
2006 Bourdet DL, Pollack GM, Thakker DR. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharmaceutical Research. 23: 1178-87. PMID 16741656 DOI: 10.1007/S11095-006-0204-Y  0.576
2006 Bourdet DL, Thakker DR. Saturable absorptive transport of the hydrophilic organic cation ranitidine in Caco-2 cells: role of pH-dependent organic cation uptake system and P-glycoprotein. Pharmaceutical Research. 23: 1165-77. PMID 16741655 DOI: 10.1007/S11095-006-0251-4  0.579
2006 McRae MP, Lowe CM, Tian X, Bourdet DL, Ho RH, Leake BF, Kim RB, Brouwer KL, Kashuba AD. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. The Journal of Pharmacology and Experimental Therapeutics. 318: 1068-75. PMID 16720753 DOI: 10.1124/Jpet.106.102657  0.332
2005 Bourdet DL, Pritchard JB, Thakker DR. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). The Journal of Pharmacology and Experimental Therapeutics. 315: 1288-97. PMID 16141367 DOI: 10.1124/Jpet.105.091223  0.571
2004 Bourdet DL, Lee K, Thakker DR. Photoaffinity labeling of the anionic sites in Caco-2 cells mediating saturable transport of hydrophilic cations ranitidine and famotidine. Journal of Medicinal Chemistry. 47: 2935-8. PMID 15139772 DOI: 10.1021/Jm030433N  0.622
Show low-probability matches.